Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTDIGC1)

• DTT Name: Dipeptidyl peptidase 4 (DPP-4) DTT Info
• Gene Name: DPP4

Molecule-Related Drug & Molecule List

7 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[1]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[2]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[3]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[4]
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[5]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[6]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[7]

20 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[8]
Gemigliptin	DMZKGPV	Diabetic complication	5A2Y	Phase 3	[9]
IDDBCP161883	DMV3DHQ	Type-2 diabetes	5A11	Phase 3	[10]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[11]
MK-3102	DM3PSUF	Type-2 diabetes	5A11	Phase 3	[12]
SAND-26	DMKHLRT	Autoimmune diabetes	5A10	Phase 3	[13]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[14]
SYR-472	DM9L1AC	Metabolic disorder	5C50-5D2Z	Phase 3	[15]
Denagliptin	DMZV3SY	Type-2 diabetes	5A11	Phase 2/3	[7]
IP10 C8	DMANRGW	Psoriasis vulgaris	EA90	Phase 2	[16]
KRP-104	DMQDLVW	Type-2 diabetes	5A11	Phase 2	[17]
Melogliptin	DMVJ6WS	Type-2 diabetes	5A11	Phase 2	[7]
P32/98	DMW1OI6	Autism spectrum disorder	6A02	Phase 2	[18]
PF-00734200	DMNM4CK	Type-2 diabetes	5A11	Phase 2	[19]
YSCMA	DMIA9JD	Haematological malignancy	2B33.Y	Phase 1/2	[20]
ARI-2243	DMN4D3A	Type-2 diabetes	5A11	Phase 1	[21]
DA-1229	DM4OTWL	Type-2 diabetes	5A11	Phase 1	[22]
REC-01	DM25GIA	Acute myocardial infarction	BA41	Phase 1	[23]
Teneligliptin	DMGJCDR	Type-2 diabetes	5A11	Phase 1	[24]
ZYDPLA 1	DMU2D0B	Type-2 diabetes	5A11	Phase 1	[25]

54 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aminopiperidine derivative 1	DMFKTJL	N. A.	N. A.	Patented	[26]
Aminopiperidine derivative 2	DM4JDHO	N. A.	N. A.	Patented	[26]
Beta-phe compound 1	DM8D3FG	N. A.	N. A.	Patented	[26]
Beta-phe compound 2	DM786OD	N. A.	N. A.	Patented	[26]
Beta-phe compound 3	DM0G8XP	N. A.	N. A.	Patented	[26]
Dihydropyrrolopyrazole derivative 1	DMHGE1T	N. A.	N. A.	Patented	[26]
Imidazo cyclohexylamine derivative 1	DM34ZCG	N. A.	N. A.	Patented	[26]
Imidazo cyclohexylamine derivative 2	DMKPAN3	N. A.	N. A.	Patented	[26]
Imidazo cyclohexylamine derivative 3	DMCQBZK	N. A.	N. A.	Patented	[26]
Imidazo pyridine derivative 2	DMC49SV	N. A.	N. A.	Patented	[26]
Peptide analog 44	DMOJDQF	N. A.	N. A.	Patented	[26]
Peptide analog 45	DMGA3U8	N. A.	N. A.	Patented	[26]
Peptide analog 46	DMC48AX	N. A.	N. A.	Patented	[26]
Peptide analog 47	DM7U8WD	N. A.	N. A.	Patented	[26]
Peptide analog 48	DMM2WA4	N. A.	N. A.	Patented	[26]
Peptide analog 49	DMP5SA2	N. A.	N. A.	Patented	[26]
Peptide analog 50	DMM8K7R	N. A.	N. A.	Patented	[26]
Peptide analog 51	DM1D7CE	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-11	DMQB4LE	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-12	DM8JIDR	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-13	DMBS2FT	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-14	DMC82UR	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-15	DMO913H	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-16	DMIFVXE	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-17	DMY4AJ7	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-18	DM0W5UA	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-21	DM2W9AP	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-34	DMX5R9N	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-37	DMMZO8Y	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-38	DMJOPEL	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-50	DMMLJ5E	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-52	DMDLPB7	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-56	DMB3DMR	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-6	DM03UK2	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-69	DMPY8NU	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-70	DMEYLM2	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-71	DMZB140	N. A.	N. A.	Patented	[26]
PMID25482888-Compound-72	DMQOVKF	N. A.	N. A.	Patented	[26]
Pyrimidine derivative 30	DMTQBUD	N. A.	N. A.	Patented	[26]
Pyrimidine derivative 31	DMOJTLU	N. A.	N. A.	Patented	[26]
Pyrimidine derivative 32	DMCUQFG	N. A.	N. A.	Patented	[26]
Pyrimidine derivative 33	DMWL5V0	N. A.	N. A.	Patented	[26]
Pyrimidinedione derivative 1	DML4OYQ	N. A.	N. A.	Patented	[26]
Pyrrolo[1,2-f]triazine derivative 1	DMI0AW7	N. A.	N. A.	Patented	[26]
Pyrrolo[1,2-f]triazine derivative 2	DM7DU9P	N. A.	N. A.	Patented	[26]
Quinazoline derivative 1	DMOBFAU	N. A.	N. A.	Patented	[26]
Thiomorpholine derivative 1	DMZP6KR	N. A.	N. A.	Patented	[26]
Thiomorpholine derivative 2	DMWOK1D	N. A.	N. A.	Patented	[26]
Triazole piperazine derivative 1	DMPRGLZ	N. A.	N. A.	Patented	[26]
Triazolo-pyrimidinedione derivative 1	DMJN72E	N. A.	N. A.	Patented	[26]
Triazolo-pyrimidinedione derivative 2	DMLGNB2	N. A.	N. A.	Patented	[26]
Tricyclic heterocycle derivative 6	DMQJK70	N. A.	N. A.	Patented	[26]
Xanthine derivative 1	DMIULVJ	N. A.	N. A.	Patented	[26]
Xanthine/amino piperidine compound 1	DMNXJ8G	N. A.	N. A.	Patented	[26]

10 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALS 2-0426	DMEKHX0	Type-2 diabetes	5A11	Discontinued in Phase 2	[27]
NVP-DPP728	DM9HKOM	Type-2 diabetes	5A11	Discontinued in Phase 2	[28]
PSN-9301	DMMF9RS	Diabetic complication	5A2Y	Discontinued in Phase 2	[29]
R-1438	DM2Q5IS	Type-2 diabetes	5A11	Discontinued in Phase 2	[7]
TA-6666	DMB3W20	Type-2 diabetes	5A11	Discontinued in Phase 2	[30]
ABT-279	DMWVFDH	Type-2 diabetes	5A11	Discontinued in Phase 1	[7]
SSR-162369	DMI3K2D	Type-2 diabetes	5A11	Discontinued in Phase 1	[7]
TAK-100	DMH16ND	Diabetic complication	5A2Y	Discontinued in Phase 1	[1]
DSP-7238	DMAE43P	Diabetic complication	5A2Y	Terminated	[24]
PT-630	DMH3RPO	Type-2 diabetes	5A11	Terminated	[3]

4 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP8497	DMRPX4W	Type-2 diabetes	5A11	Preclinical	[7]
ER-319711-15	DMBINP0	Type-2 diabetes	5A11	Preclinical	[7]
LY-2463665	DM7XPDB	Type-2 diabetes	5A11	Preclinical	[7]
PT630	DM9SY8E	Colon cancer	2B90.Z	Preclinical	[31]

47 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+/-)-6-(2-chlorophenyl)cyclohex-3-enamine	DM23W58	Discovery agent	N.A.	Investigative	[32]
(1-phenylcyclopentyl)methanamine	DM0TUKZ	Discovery agent	N.A.	Investigative	[33]
(1R,2R)-1,2-diphenylethane-1,2-diamine	DM18E9D	Discovery agent	N.A.	Investigative	[34]
(1R,2S)-1,2-diphenylethane-1,2-diamine	DM28D9E	Discovery agent	N.A.	Investigative	[34]
(2-(2-chlorophenyl)pyridin-3-yl)methanamine	DMYOTMP	Discovery agent	N.A.	Investigative	[34]
(2-chloro-6-phenoxyphenyl)methanamine	DMOS864	Discovery agent	N.A.	Investigative	[34]
(2s)-Pyrrolidin-2-Ylmethylamine	DMZON3T	Discovery agent	N.A.	Investigative	[35]
(3S,4R)-3-butyl-1-phenylpiperidin-4-amine	DMAEXO3	Discovery agent	N.A.	Investigative	[36]
(5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine	DM2HCUK	Discovery agent	N.A.	Investigative	[37]
(R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid	DMGD026	Discovery agent	N.A.	Investigative	[38]
(S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone	DMWBH9N	Discovery agent	N.A.	Investigative	[39]
(S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione	DMORFZE	Discovery agent	N.A.	Investigative	[40]
(S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone	DMXVQJI	Discovery agent	N.A.	Investigative	[41]
(S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone	DM16N7Z	Discovery agent	N.A.	Investigative	[42]
1-benzhydryl-3-butylpiperidin-4-amine	DMBAZG3	Discovery agent	N.A.	Investigative	[36]
1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine	DMGDY4X	Discovery agent	N.A.	Investigative	[43]
1-biphenyl-2-ylmethanamine	DMKJYCU	Discovery agent	N.A.	Investigative	[33]
2-(2-chlorophenyl)-2-morpholinoethanamine	DMFG2S5	Discovery agent	N.A.	Investigative	[34]
2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One	DM6AYDL	Discovery agent	N.A.	Investigative	[44]
3-butyl-1-(naphthalen-1-yl)piperidin-4-amine	DMXF8M0	Discovery agent	N.A.	Investigative	[36]
4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine	DMCGOPQ	Discovery agent	N.A.	Investigative	[43]
4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine	DMRMAOI	Discovery agent	N.A.	Investigative	[43]
4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine	DMJMOAI	Discovery agent	N.A.	Investigative	[45]
ABT-341	DMZ3YTO	Discovery agent	N.A.	Investigative	[32]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[44]
ASC-201	DM5WR0L	Bone marrow transplantation	QB63.6	Investigative	[24]
BPI-711001	DMOSG0Q	Hypoglycemia	5A41	Investigative	[24]
C-(2'-Chloro-biphenyl-2-yl)-methylamine	DMNMYWI	Discovery agent	N.A.	Investigative	[34]
Cyclohexylglycine-(2S)-cyanopyrrolidine	DMNG4B1	Discovery agent	N.A.	Investigative	[46]
D-420720	DM048OG	Diabetic complication	5A2Y	Investigative	[24]
D-Val-L-boroPro	DML4G6K	Discovery agent	N.A.	Investigative	[47]
DB-160	DMEST0R	Non-insulin dependent diabetes	5A11	Investigative	[24]
Diisopropylphosphono Group	DMND2AS	Discovery agent	N.A.	Investigative	[44]
DIPROTIN A	DMGBCP0	Discovery agent	N.A.	Investigative	[48]
E-3024	DME5JBH	Discovery agent	N.A.	Investigative	[49]
EMC-0901	DMUH1JX	Diabetic complication	5A2Y	Investigative	[24]
FE 999011	DMKVA6Z	Discovery agent	N.A.	Investigative	[50]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[44]
Iodo-Phenylalanine	DMF8EJ6	Discovery agent	N.A.	Investigative	[44]
KR-62436	DM7G8KR	Non-insulin dependent diabetes	5A11	Investigative	[51]
L-Ala-L-boroPro	DMH6XTP	Discovery agent	N.A.	Investigative	[47]
L-Val-L-boroPro	DMPGT80	Discovery agent	N.A.	Investigative	[47]
N-isoleucylthiazolidine	DM53AS0	Discovery agent	N.A.	Investigative	[46]
N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine	DMARZHU	Discovery agent	N.A.	Investigative	[52]
PK-44	DM40HWI	Non-insulin dependent diabetes	5A11	Investigative	[24]
PMID20684603C24dd	DMWZK9U	Discovery agent	N.A.	Investigative	[53]
Retagliptin	DMQFSI5	Non-insulin dependent diabetes	5A11	Investigative	[24]

References

• [1] Clinical pipeline report, company report or official report of Takeda (2009).
• [2] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [7] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [8] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
• [9] Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41.
• [10] Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95.
• [11] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [12] Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.
• [13] Clinical pipeline report, company report or official report of Siesonline.
• [14] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [15] SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32.
• [16] Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
• [17] Clinical pipeline report, company report or official report of Activx.
• [18] Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002 Apr;51(4):943-50.
• [19] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabet Med.2011 Apr;28(4):464-9.
• [20] Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol. 2014 Feb 6;9:30.
• [21] Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clin Proc. 2010 December; 85(12 Suppl): S27-S37.
• [22] DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012 Jan 2;90(1-2):21-9.
• [23] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
• [25] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [26] DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
• [27] Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews April 2012 vol. 64 no. 2 188-237.
• [28] A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem. 2008 Aug;43(8):1603-11.
• [29] Navigating the chemical space of dipeptidyl peptidase-4 inhibitors. Drug Des Devel Ther. 2015; 9: 4515-4549.
• [30] Dipeptidyl Peptidase-4 Inhibitors Clinical data and clinical implications. before print March 2, 2007.
• [31] Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25.
• [32] Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)... J Med Chem. 2006 Nov 2;49(22):6439-42.
• [33] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [34] In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9.
• [35] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [36] 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70.
• [37] Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2362-7.
• [38] Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13.
• [39] New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4770-3.
• [40] Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett. 2002 Oct 21;12(20):2825-8.
• [41] Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem. 2008 Feb 15;16(4):1613-31.
• [42] [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2618-21.
• [43] Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12.
• [44] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [45] Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2006 Jan 1;16(1):123-8.
• [46] 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioava... J Med Chem. 2006 Jan 12;49(1):373-80.
• [47] Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8.
• [48] Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84.
• [49] E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.Eur J Pharmacol.2006 Oct 24;548(1-3):181-7.
• [50] Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes. 2002 May;51(5):1461-9.
• [51] Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem. 2009 Mar 1;17(5):1783-802.
• [52] Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4777-9.
• [53] Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.